Skip to main content

Table 1 Histone modifications and associated MRM transitions used for quantification

From: Histone post-translational modifications in frontal cortex from human donors with Alzheimer’s disease

Histone

Sequence

Precursor ion (m/z)

Product ion (m/z)

H2A

AGLQFPVGR

472.796 (2+)

703.39 (1+, y6)

H2A (canonical)

VTIAQGGVLPNIQAVLLPK

966.08 (2+)

1092.68 (1+, y10)

H2A (1-A, 2-B, H2Ax)

LLGGVTIAQGGVLPNIQAVLLPK

757.80 (3+)

546.84 (2+, y10)

H2B

EIQTAVR

408.73 (2+)

446.27 (1+, y4)

H2B, K108-methylation

LLLPGELAKme

484.31 (2+)

736.46 (1+, b7)

H2B, K120-ubiquitination

AVTKubYTSSK

549.79 (2+)

827.43 (1+, y6)

H3

DIQLAR

358.21 (2+)

359.24 (1+, y3)

H3, K4-, K9-acetylation

KacQLATKacAAR

535.82 (2+)

772.47 (1+, y7)

H4

VFLENVIR

495.29 (2+)

501.31 (1+, y4)

H4, K8-, K12-, K16-acetylation

GGKacGLGKacGGAKacR

606.34 (2+)

927.54 (1+, y9)

H4, K12-, K16-acetylation

GLGKacGGAKacR

464.27 (2+)

530.30 (1+, y5)

H4, R55-methylation

ISGLIYEETRme

597.82 (2+)

290.18 (1+, y2)

  1. Modifications (ac) acetylation, (me) methylation, and (ub) ubiquitination of peptides were measured and normalized to an unmodified peptide, shown in italics, from the respective histone